13 October 2023 in Journal of Education, Health and Sport
Depressive disorders are a widespread problem in modern medicine. According to current data from the World Health Organisation, an estimated 280 million people worldwide suffer from depression. In recent years, there have been reports of a correlation between the composition of the gut microbiota and the development of depressive disorders and attempts to modify it through the use of psychobiotics. The literature from the PubMed database published between 2018-2023 has been explored. 596 articles were selected based on the keywords "probiotics" and "depression". Six randomized clinical trials were finally included in the analysis. As defined elsewhere, psychobiotics are probiotic bacteria which supplemented in adequate amounts, interact with the gut-brain axis and show beneficial effects on patients' mental health. Results from recent RCTs suggest that daily probiotic supplementation significantly reduces the severity of depression compared to placebo (p<0.05). Additionally, this effect may be enhanced by the combined use of a probiotic with a prebiotic. Furthermore, some researchers indicate that probiotics may lead to significant improvements in cognitive function in patients suffering from depressive disorders. In conclusion, intestinal dysbiosis may be an important factor leading to the development of mental illness. Results of recent studies suggest that specific strains of probiotic bacteria may offer therapeutic benefits in the treatment of the aforementioned disorders. However, further clinical studies are needed to objectively confirm the relationship between gut microbiota composition and the development of depression.
7 September 2022 in Journal of Pre-Clinical and Clinical Research
Histamine is a biogenic amine, which occurs naturally in the human body. Histamine can be metabolised with Diamine Oxidase (DAO) Enzyme. It is estimated that in 1% of people, as a result of an imbalance between the supply and degradation of histamine, a condition called histamine intolerance...
1 September 2020 in Journal of Education, Health and Sport
Introduction Helicobacter pylori (H. pylori) infection is prevalent worldwide. As it is a known carcinogen, causing multitude of gastrointestinal end extra-gastric disorders, the eradication therapy is now indicated for every patient diagnosed with this infection. This approach may prove however to be improper, since it is now known, that not every strain of this species is pathogenic, therapy may be unsuccessful and drug resistance is ever increasing problem. A brief description of the state of knowledge: H. pylori is a species representing multiple strains with distinct regional genetic markup. Its prevalence is high in the general population, but in the recent years there have been reports of decreased presence in the developed countries. This paper reviews most important known genetic diversity markers and their impact on virulence and toxicity of species. It also covers possible new ways to combat the infection. Conclusion With increased possibility of genetic sequencing, there may be possibility for custom-tailored eradication therapy of H. pylori in the future.
13 October 2023 in Journal of Education, Health and Sport
Background: Proton pump inhibitors (PPIs) are widely used drugs that reduce gastric acid secretion. In recent years, there has been a gradual increase in their use. The safety of prolonged PPI therapy and the potential for cumulative side effects of these drugs raise legitimate concerns. An association between PPI administration and the risk of Clostridioides difficile infection has been suggested. The findings regarding this phenomenon require further unequivocal verification. Material and methods: A review of publications obtained from the PubMed database and published between 2016-2023. Based on the keywords "proton pump inhibitor", "PPI" and "Clostridium", 132 articles were selected. Finally, 6 meta-analyses were included in the analysis. Results: Studies conducted in recent years have shown a statistically significant increase in the risk of C. difficile infection in patients taking PPIs compared to those who avoid this therapy. The aforementioned relationship was observed in both adults and pediatric patients. One study proved that the risk remained high even up to 1 year after the end of treatment. The described relationship is still a matter of debate due to the fact that patients using antacids are usually elderly, have several comorbidities and a higher risk of developing C. difficile infection regardless of PPI use. Conclusions: The relationship between the use of PPIs and the risk of developing C. difficile infection is still controversial, which justifies the need for continued clinical trials to objectively resolve this issue. PPIs exert high efficacy in the treatment of acid-dependent diseases, but due to the many ambiguities surrounding possible side effects, caution in their administration seems warranted, especially for long-term therapy in elderly patients with polypharmacy.
22 June 2023 in European Journal of Translational and Clinical Medicine
Abdominal pain is one of the main symptoms of pancreatic diseases, including chronic pancreatitis (CP). Once the disease is in remission, pain management is a key element of treatment. Co-analgesics may also be used at any stage of analgesia, among which antiepileptic drugs such as pregabalin. The first data on the beneficial effect of pregabalin on pain in the course of CP was published in a clinical trial in 2011, and it has been known since 2015 that the analgesic effect of pregabalin on CP has a different mechanism of action than conventional analgesics. Currently, research is focused on combining pregabalin with antioxidants and on methods to predict the patient’s response to pregabalin administration. Based on current research, pregabalin appears to be a very useful agent for the pharmacologic treatment of pain in the setting of CP.
7 August 2024 in Journal of Pre-Clinical and Clinical Research
Introduction: Gastrointestinal stromal tumours (GISTs) are considered the most common mesenchymal lesions of the gastrointestinal tract, despite accounting for less than 1% of cancers diagnosed in this area. They frequently occur in the stomach and small intestine, rarely in the colon and...